AXSM Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -61.67% compared to Axsome Therapeutics's net margin of -49.65%. Axsome Therapeutics's return on equity of -194.28% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Axsome Therapeutics has a consensus price target of $130.47, signalling upside risk potential of 48.31%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 557.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Axsome Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 1.177, which suggesting that the stock is 17.723% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $104.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Axsome Therapeutics's net income of -$64.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.38x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -61.67% compared to Axsome Therapeutics's net margin of 25.23%. Axsome Therapeutics's return on equity of -194.28% beat Pfizer's return on equity of 4.63%.

Axsome Therapeutics has a consensus price target of $130.47, signalling upside risk potential of 48.31%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.97%. Given that Axsome Therapeutics has higher upside potential than Pfizer, analysts believe Axsome Therapeutics is more attractive than Pfizer.

Axsome Therapeutics has a beta of 1.177, which suggesting that the stock is 17.723% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.33% to investors and pays a quarterly dividend of $0.42 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $104.8M, which are smaller than Pfizer quarterly revenues of $17.7B. Axsome Therapeutics's net income of -$64.6M is lower than Pfizer's net income of $4.5B. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.38x versus 2.54x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -61.67% compared to Axsome Therapeutics's net margin of -2357.27%. Axsome Therapeutics's return on equity of -194.28% beat Palatin Technologies's return on equity of --.

Axsome Therapeutics has a consensus price target of $130.47, signalling upside risk potential of 48.31%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Axsome Therapeutics, analysts believe Palatin Technologies is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 1.177, which suggesting that the stock is 17.723% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $104.8M, which are larger than Palatin Technologies quarterly revenues of $350K. Axsome Therapeutics's net income of -$64.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.38x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of -61.67% compared to Axsome Therapeutics's net margin of -0.42%. Axsome Therapeutics's return on equity of -194.28% beat Repligen's return on equity of -0.41%.

Axsome Therapeutics has a consensus price target of $130.47, signalling upside risk potential of 48.31%. On the other hand Repligen has an analysts' consensus of $191.46 which suggests that it could grow by 31.34%. Given that Axsome Therapeutics has higher upside potential than Repligen, analysts believe Axsome Therapeutics is more attractive than Repligen.

Axsome Therapeutics has a beta of 1.177, which suggesting that the stock is 17.723% more volatile than S&P 500. In comparison Repligen has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.502%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $104.8M, which are smaller than Repligen quarterly revenues of $154.9M. Axsome Therapeutics's net income of -$64.6M is lower than Repligen's net income of -$654K. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Repligen's PE ratio is 628.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.38x versus 12.93x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.